StartupsTechFundingNewsabout 1 hour ago
Ascensia Leads $36M Series B for Sava
3 min read
London-based Sava Technologies announced a $36 million Series B funding round led by Ascensia Diabetes Care. The company aims to eliminate fingerstick glucose testing within 18 to 24 months after securing CE approval. Total funding reaches $68 million, supporting manufacturing expansion for its skin-placed microsensors.
Level
Hype check
Tap to vote and see what everyone thinks.
